June 18 (Reuters) - Medicenna Therapeutics Corp MDNA.TO :
* MEDICENNA PRESENTS PRELIMINARY TOP-LINE CLINICAL RESULTS FROM THEIR PHASE 2B TRIAL OF MDNA55 IN RECURRENT GLIOBLASTOMA
* MEDICENNA - SAFETY DATA FROM PHASE 2B CLINICAL TRIAL SHOW SIMILAR SAFETY PROFILE TO PREVIOUS MDNA55 TRIALS
* MEDICENNA THERAPEUTICS CORP - DISEASE CONTROL RATE OF UP TO 83% ACHIEVED; EVIDENCE OF IMPROVED SURVIVAL FOR PATIENTS